The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.
[Journal of Hepatocellular Carcinoma] A review of the manifestations, treatments, and challenges associated with hepatocellular cancer pain.
[Journal of Hepatocellular Carcinoma] In this case series, the authors present procedure and treatment specifics for 2 patients with HCV who developed HCC, and discuss the potential role of DAA therapy and immunosurveillance.
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Patients with alcohol-related HCC displayed reduced OS when compared to patients with non-alcohol-related HCC.
[Gastrointestinal Cancer: Targets and Therapy] This review discusses novel tools and newer technologies that have been employed to address iCCA.
Results of the prospective CHANGH study demonstrate the effect of alcohol consumption on early diagnosis, management, and overall survival for patients with hepatocellular carcinoma.
Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
